medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2006, Number 1

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2006; 23 (1)

Juvenile Diabetes Preclinic Phase Diagnosis. A Pediatrician Challenge.

Covarrubias-Espinoza R

Language: Spanish
References: 17
Page: 31-34
PDF size: 35.57 Kb.


ABSTRACT

The prevalence of diabetes worldwide has grown considerably, estimating that by the year 2025 an average of 300 million people would suffer from this problem, and probably México would be in seventh place. The total number of deaths related in Latinamerica and the Caribbean could rise around 300,000 each year. The clinical symptoms of the disease are the results of a slow destruction of insulin production cell process of autoimmune nature and initiates mainly in genetic suceptibles individuals combined with environment factors, it works by a cytokine (interferon Alpha, FNT, interleukin) mediated response, that are the responsables of the destruction of B cells. Each time is more frecquent the grave Ketoacidosis presentation and being of our interest to try to motivate the clinician to identify the symptoms before the beginning of the disease, being necessary more research on the matter and establishing more preventive studies on familial backgrounds with insulin-dependent diabetes mellitus of higher risk of developing clinical symptoms in our environs.


REFERENCES

  1. 1.- Covarrubias E.R. Excreción Urinaria de Proteínas en Niños Diabéticos. Bol Clin Hosp. Inf. Edo. Son. 2003; 20: 30-4.

  2. 2.- García Hernán B. Factores de riesgo y prevención en diabetes mellitas tipo 1. Actualización. Rev. Chil. Pediatr. V.72 N. 4 Santiago Jul. 2001.

  3. 3.- Hathout H Eba, MD Endy Thomas, Mohamed El-Shahawy. Marcadores Autoinmunes en niños y adolescentes diabéticos. Pediatrics Vol. 17 No. 6 Junio 2001.

  4. 4.- Grosembacher L.A. y colaboradores. Prevalencia de marcadores de riesgo genético e inmunológico en familiares sanos de diabéticos tipo 1. Endocrinología y Medicina Nuclear y Pediatría del Hospital Italiano de Buenos Aires. Trabajo Ganador del Premio Escudero de la Sociedad Argentina de Diabetes 2000. http:// www.nutrinfo.com.ar.

  5. 5.- Treatment of prediabetic patients with insulin: Experience and future. European Prediabetes Study Group Carel JC, Bougneres PF. Horm Res 1996; 4 (Suppl 1): 44-7.

  6. 6.- Sabbah E, Savola K, Ebeling T: er al: Genetic, autoimmune, and clinical characteristics of childhood and adult-onset type I diabetes. Diabetes Care 2000; 23: 1326-32.

  7. 7.- Estimación de la Mortalidad Mundial por todas las causas y diversas regiones. 1999WHO.

  8. 8.- Lic. Warren Hart, Collazo Herrera M. Costos del diagnóstico y tratamiento de la diabetes mellitus en diferentes países del mundo. Rev. Cubana Endocrinol 1998; 9(3): 212-20.

  9. 9.- Dahlquist G. Enviromental risk factors in human type 1 diabetes. An epidemiological perspective. Diabetes Metab Rev 1995; 11: 37-46.

  10. 10.- Aguilar M. Epidemiología y etiopatogenia de la diabetes mellitas tipo 1. En: Herrera Pombo ed. Actualización en Endocrinología. Drug.Madrid. 1997; 11-26.

  11. 11.- K.Decochez, B.Keymeulen, G.Somers, H.Dorchy, F.Gorus. El uso de anticuerpos anti-islotes para identificar a pacientes con diabetes tipo 1 que presentaran una rápida disminución del péptido C, luego del comienzo clínico. Diabetes Care 2000-08-20; 23. 1072-8.

  12. 12.- Feeney SJ, Myers MA, Mackay IR, et al. Evaluation of ICA512As in combination with other islet cell autoantibodies at the onset of IDDM. Diabetes Care 1997; 20: 1403-7.

  13. 13.- M Christie, Roll U, Payton MA, Hatfield ECI, Ziegler AG. Validity of screening for individuals at risk for type 1 diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care 1997; 20: 965-70.

  14. 14.- RJ Keller, Eisenbarth GS, y Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-8.

  15. 15.- RB Elliot, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes in children using nicotinamide. Diabetologia 1991; 34: 362-6.

  16. 16.- Gale Edwin AM. European Nicotinamide Diabetes Intervention Trial (Endit): a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-31..

  17. 17.- Curr Drug Targets Immune Endocr Metabol Disord.2005 Jun;5(2): 227-36.




2020     |     www.medigraphic.com